Compare Snap Inc (SNAP) vs TG Therapeutics Inc (TGTX) Price & Performance

Snap stock trades at $5.865, up 0.95% on the day, with a bullish technical signal from moving averages. Revenue grew to $5.93 billion in 2025, and net losses narrowed to -$460 million, showing improving profitability. Recent news highlights the launch of SPECS Intelligence AI and enterprise partnerships with NVIDIA and Salesforce, driving positive sentiment. The consensus price target is $7.78, with 38% of analysts rating it a Buy.

The outlook remains cautious but improving, as revenue growth and narrowing losses present opportunity, but persistent net losses and high debt pose risks. Regulatory pressures and intense social media competition are key challenges. Analyst consensus leans Hold, reflecting a wait-and-see approach amid ongoing transformation efforts.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.